Hallux Valgus – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Hallux Valgus Market Outlook

Thelansis’s “Hallux Valgus Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hallux Valgus treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hallux Valgus Overview

Hallux valgus (HV), commonly known as a bunion, is a prevalent deformity affecting the forefoot. HV is characterized by lateral deviation of the proximal phalanx and medial deviation of the first metatarsal head, resulting from the adduction of the first metatarsus, known as metatarsus primus varus. The exact cause of HV is not fully understood, but it is likely the result of multiple contributing factors. These factors include genetics, a shortened first metatarsal, dorsiflexion (upward bending) of the first metatarsal, flexible or rigid varus deformity of the forefoot, flexible or rigid pes planovalgus (flatfoot), gastrocnemius equinus (tight calf muscles), abnormal foot mechanics, and joint hypermobility. HV deformity is commonly observed in individuals with connective tissue disorders such as Marfan syndrome, Ehlers-Danlos syndrome, and those with Down syndrome. The pathophysiology of HV is complex, involving an imbalance between the extrinsic and intrinsic muscles of the foot, along with the involvement of ligaments. The alignment of the first metatarsal is maintained through tension created by the peroneus longus muscle laterally and the abductor hallucis muscle medially. Other conditions to consider when evaluating patients with suspected HV deformity include osteoarthrosis, Freiberg disease, hallux rigidus, Morton neuroma, turf toe, gout, and septic joint. Physical examination is typically sufficient for diagnosing hallux valgus deformity, but imaging is important to assess potential damage to the first metatarsophalangeal (MTP) joint. Treatment options for HV deformity include both non-surgical and surgical approaches. The prognosis for HV deformity is generally favorable. Complications associated with HV deformity may include bursitis (most common), hammertoe deformity of the second toe, degenerative disease of the metatarsal head, central metatarsalgia, entrapment of the medial dorsal cutaneous nerve, and synovitis of the MTP joint. HV deformity is more prevalent in women than in men.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2024–2034)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…


Read more: Hallux Valgus – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Comments

Post a Comment